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Objectives: To determine claudication patients’ risk attitude to invasive treatment and whether this treatment is cost
effective.
Methods: Quality of life and health state utility status of 50 consecutive patients with severe intermittent claudication was
assessed and compared with ankle-brachial pressure index values (ABPI) and results from treadmill tests before and after
endovascular or open revascularization. Health utility scores were then calculated and used in a cost-utility analysis.
Results: Before surgery, patients were assigned a utility score of 0.51 (EQ-5D index) for their disease, and the standard
gamble (SG) and time trade-off (TTO) median scores were 0.88 and 0.70, respectively. Before treatment, a weak
correlation (r  0.43, P < .001) between having a high risk perception of treatment and patients’ walking distance were
observed, where patients able to walk short distances accepted a higher risk. After treatment, ABI (P .003) and walking
distance (P  .002) improved significantly as well the physical components of the quality of life instruments (P < .001).
The surgical treatment generated an improvement in quality of life expressed in QALYs equivalent to 0.17. With an
estimated survival of 5 years, it adds up to a value of 0.85, corresponding to a sum of 51,000 US$ gained.
Conclusions: Patients with severe intermittent claudication are risk-seeking when it comes to surgical treatment and their
risk attitude is correlated to their walking ability and quality of life. The incremental QALYs gained by treatment are
achieved at a reasonable cost and revascularization appears to be cost effective. ( J Vasc Surg 2008;47:988-94.)Intermittent claudication (IC) is a common disease
that afflicts 6% to 7% of persons over age 55 in populations
of Western countries.1,2 This disease is also a known
marker for early cardiovascular death, and patients should
be recommendedmeasures to reduce this risk.3,4 The prog-
nosis regarding the leg symptoms, on the other hand, is
considered to be relatively benign and usually only a frac-
tion of patients with IC is judged suitable for revasculariza-
tion. This approach is motivated by the notion that it is a
benign disease and that noninvasive treatment is safe and
has acceptable results. The benefits of exercise training
program has shown to improve event-free survival for pe-
ripheral artery disease (PAD) patients as well as prevent and
treat many established atherosclerotic risk factors.5 Surgical
treatment achieves a better outcome but is related to risks
that are a part of the treatment.6-9 These fundamentals have
lately been challenged. It is possible, for example, that the
surgical risk is exaggerated, particularly for endovascular
treatment. Furthermore, patients generally consider them-
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988selves severely disabled and their health related quality of
life (HRQL) is significantly impaired physically as well as
socially.10-13 There may also be a gap between patients’ and
vascular surgeons’ appraisal of surgical risk and perception
of symptoms. Such a gap could be managed more appro-
priately if better estimations of risk and understanding of
risk attitudes were available. This information could be
important for individualized preoperative information and
could possible also influence treatment indications.
Accordingly, the hypothesis in this study was that pa-
tients with severe IC are willing to accept a substantial risk
with their treatment, and the primary purpose of this study
was to evaluate IC patients’ perception of their symptoms
and HRQL in relation to their risk attitude to treatment.
Second, we aimed to assess if invasive treatment improves
HRQL and consequently is cost effective.
METHODS
Patients
Fifty consecutive patients with severe IC (Rutherford’s
category 3)14 who were on the waiting list for an invasive
procedure were enrolled. The treatment decision was taken
prior to inclusion in the study by one of the six surgeons
practicing at the hospital. The patients represented a pop-
ulation referred for treatment evaluation of their IC to the
Department of Vascular Surgery. Inclusion criteria, besides
a scheduled procedure, were a medical history of a pain free
walking distance 200 meters without any other known
conditions limiting their walking distance. Patients were
excluded if previously treated for PAD by endovascular or
open surgery. The study was designed to reflect patients’
symptoms, thus using a societal and patient perspective,
and did not stratify patients according to type of procedure.
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about their disease before treatment. The mean age of the
group was 66.9 (range 45-83). Additional demographic
characteristics, risk factors, and concomitant diseases are
presented in Table I.
Procedure
Before and 6 months after invasive treatment, HRQL
was assessed by three questionnaires; SF-36, EQ-5D self-
classifier, and Walking Impairment Questionnaire (WIQ).
All patients were asked to complete the questionnaires at
home. On the day of admission and at 6 months follow-up,
patients also underwent a treadmill test to determine their
absolute claudication distance (ACD). The treadmill was
set at 3 mph/h,15 starting at a grade of 0% that increased
2.5% every 3 minutes until the test was stopped because
ACD was reached. An interview was performed by one of
the authors (AL), which covered patients’ risk attitude and
preference to a particular health state (health utility) and
included one standard gamble (SG) and one time trade-off
(TTO) question. At the interview 6 months after invasive
treatment the patients were asked to re-evaluate their pre-
operative status, ie, they were asked to imagine the situation
before their invasive procedure when responding to the
health utility questions.
Data concerning their demography, general medical
condition, ankle-, and brachial blood pressure as well as
ankle-brachial blood pressure index (ABPI) were collected
from the patients’ medical records before and after treat-
ment. True cost per patient was estimated from the hospi-
tal’s inpatient fiscal database.
Questionnaires
SF-36 is a generic instrument that is used to assess
HRQL in a wide range of health problems including vas-
cular diseases. It contains 36 questions covering eight
health domains that are summarized in the physical com-
ponent summary (PCS) and the mental component sum-
mary (MCS). For this study, the standard Swedish version
Table I. Demographic characteristics, risk factors, and
concomitant diseases of the patients with claudication
enrolled in the study (n  50)
Numbers Valid percent
Male/female 30/20 60/40
Working/retired 20/30 40/60
Married 33 66
Widowed 5 10
Previous/current smoker 23/27 46/54
Diabetes mellitus 10 20
Angina 6 12
Previous MI 9 18
Hypertension 28 56
Previous stroke or TIA 3 6
Chronic obstructive pulmonary disease 4 8
MI, Myocardial infarction; TIA, transient ischemic attack.of SF-36 was used.16,17EQ-5D self-classifier is another HRQL instrument that
is used as a complement to other instruments, including
disease-specific ones.18,19 It consists of three parts; a self-
classifier, a rating scale (EQ-5D VAS), and a set of demo-
graphic questions. Respondents classify their health status
in five dimensions—mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression within three
levels: (1) no problems, (2) moderate problems, and (3)
severe problems.
WIQ is a disease-specific questionnaire for patients with
PAD and has been validated against the treadmill test.20,21
It assesses walking distance, walking speed, and stair-climbing
ability. Symptom scores range from 0% (patients perceive
much difficulty) to 100% (no difficulty). In this study, one
additional item was added to the questionnaire, which was
phrased as follows: “How has your limited walking ability
affected your daily life?” The answers could be given rang-
ing from 0 (very much) to 4 (not at all).
Health state utility
Preference based measures estimate patients’ appraisal
or desirability of a particular health state. Preference scores
allow integration of impaired quality and quantity of life. It
is expressed as a health state utility score ranging from 0
(dead) to 1 (full health). Three well established methods
were used to obtain health state utility values; EQ-VAS,
TTO, and SG. For social health state utility values, the UK
EQ-5D index was used. For the EQ-VAS method, the
respondent locates the health state to be assessed on a
vertical line from 0-100 with dead and full health as end
points. The TTO method reveals the patients underlying
preference for a specific outcome and was developed by
Torrance et al.22 With this method, the quality weight of a
health state is assessed by comparing T years in the health
state with X years in full health. The number of years in full
health is varied until the individual is indifferent between
the alternatives, and the quality weight of the health state is
equal to X/T.
The TTO question in this study was framed as follows;
“Imagine that you have 10 years left to live. In connection
with this, you can choose to live these 10 years with your
current walking limitations, or you can choose to live a
shorter life without any symptoms from your legs. Tell me
the number of years without any symptoms from your leg
that is of equal value to 10 years in your current health
state?” Since the TTO method was used to obtain the UK
EQ-5D index, it is considered to indirectly also reflect an
individual’s risk attitude.
The SG method captures a person’s risk attitude and
has its foundation in the von Neumann-Morgenstern ex-
pected utility theory. According to this theory, the standard
gamble method can be used to estimate a cardinal utility
function for different outcomes. With this method, the
individuals are offered two choices. Choice A is a hypothet-
ical treatment with two possible outcomes: the first, return-
ing to full health for 10 years (probability P) or the second,
immediate death (probability 1- P). The alternative choice
B is the certain outcome that he or she will stay in their
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until the patient is indifferent between choice A and B. If
for example the individual is indifferent between 10 years in
the current health state and a gamble with a 60% probability
of full health in 10 years and a 40% probability of immediate
death. The expected utility of the gamble is 6 (0.6  10 
0.4  0) and the expected utility of 10 years in the current
health state is 6 (1  6). The method can thus be inter-
preted as measuring the fraction of the utility of full health
for a health state. This fraction is then used as the quality
weight to construct QALYs. In this study, the patients were
asked to answer the question, “How great a risk would you
accept with treatment in order to be fully recovered from
your walking limitations?” More detailed descriptions of
TTO, SG, and these techniques have been published
previously.23,24
Cost-utility analysis
Cost-utility analysis is chosen whenHRQL is an impor-
tant outcome of treatment. It combines length of life and
health status into a single measure useful for economic
evaluations. One measure that reflects this is quality ad-
justed life years (QALY). In cost-utility analysis QALYs are
included to compare the incremental health effects of man-
agement with the costs associated with it.21 In this study,
we used the health state values in the UK EQ-5D index
tariff to obtain QALYs. This tariff assigns a single index
value for all 243 possible health states classified by the
EQ-5D. The social tariff is based on data generated from a
national general public survey in UK using the TTO
method to elicit mean TTO values for different health
states.25
The QALY gained by a treatment can be converted to a
monetary value by calculating the cost of treatment corre-
sponding to one QALY gained. If a treatment is cost
effective, its costs have to be below a specific threshold.
There is no consensus on the threshold for cost effective-
ness in the literature, and the frequently quoted US thresh-
old of $50,000/QALY has recently been challenged.26 In
this study, we used the recommendations made by the
National Institute for Health and Clinical Excellence
(NICE) in the United Kingdom. NICE makes its decisions
on case-by-case basis rather than using absolute thresholds
when making recommendations. The consensus among
NICE’s economic advisers is that NICE should, generally,
accept as cost effective those interventions with an incre-
mental cost-effectiveness ratio (ICER) of less than £20,000
per QALY.27 Since we use QALYs instead of life years
gained as the effectiveness measure, the effectiveness ratio
will be calculated with the cost of treatment divided with
the QALY gained multiplied by the expected life years. We
used a long-term survival rate of 5 years for the cost-utility
calculation in this study. This was based on the 5, 10, and
15 years mortality rate (all causes) in the literature for IC,
which is 30%, 50%, and 70%, respectively.9Statistical analysis
Student t test was used to make comparisons of ABPI
and tread mill test parameters before and after treatment.
Because HRQL data and utility values (SF-36, WIQ, EQ-
5D, and utility values) were skewed, nonparametric meth-
ods were used for analysis of these variables: Wilcoxon
signed rank test and, for correlations, the Spearman-rank.
Data was displayed as mean, standard deviation (SD) me-
dian with 95% confidential intervals (95% CI) or range
(minimum and maximum). Box-plots were used to display
HRQL and health utility data, presenting median, 25% and
75% quartiles, and upper and lower extremes. Statistical
significance was defined as P .05. Statistical analyses were
performed by SPSS version 14.0 (SPSS Inc, Chicago, Ill).
Ethical considerations
The local ethics committee at Karolinska University
Hospital approved the study. (Dnr 00-434). Before enter-
ing the study, each patient gave consent to participate.
RESULTS
Clinical parameters
Endovascular treatment was performed in 29 patients
(58%). Of these, 25 underwent treatment for suprainguinal
disease and four, for angioplasty in the superficial femoral
artery (SFA) above the knee. Bypass surgery was performed
in 21 patients (42%), all done with synthetic grafts. All but
one underwent a femoropopliteal bypass above the knee.
One patient had a femoropopliteal bypass with the distal
anastomosis placed in the popliteal artery below the knee.
The distribution of unilateral vs bilateral disease was 19 and
31, respectively. Unilateral treatment was performed in 17
of the patients with bilateral disease.
At 6 months, all 50 patients were included in the
follow-up and none of the patients had been amputated nor
had graft occlusion or stenosis occurred. ABPI increased
from 0.60 (SD 0.27) to 0.73 (SD 0.21 P  .003) after
revascularization and ACD changed from 63 meters (SD
4.0) to 140 meters (SD 16.0 P  .001). Time to onset of
claudication increased from 1.33 minutes (SD 1.07) to
2.16 minutes (SD 2.69 P  .001).
Health related quality of life
SF-36, EQ-5D self-classifier, and WIQ. The SF-36
domains physical functioning (P  .001), role-physical
(P  .006), bodily pain (P  .001), and social functioning
(P  .05), improved after revascularization, as well as all
WIQ dimensions (P  .001). The results are presented in
Figs 1 through 3. Also, the EQ-5D domains mobility (P 
.001), usual activity (P  .05) and pain (P  .004) was
enhanced. A majority of the patients scored moderate
problems in the two dimensions mobility and pain both
before and after revascularization. Their reported com-
plaints are presented in Table II.
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EQ-5D index, EQ-VAS, TTO, and SG. The utility
values for the EQ-5D index (P  0.001) and the EQ-
VAS (P  .02) also improved significantly after revascu-
larization. No differences were observed in the patients’
scores for TTO and SG questions assessing the preoper-
ative status both before and after treatment (Table III).
Furthermore, no significant differences regarding the
TTO and SG values were seen before or after open
revascularization or interventional procedures. The health
utility value for the TTO questions revealed that living
for 10 years in the current health state was equal to living
7 years (median) without walking limitations. The SG
question demonstrated that the risk-willingness with
treatment was 13% (median). Accordingly, patients ac-
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Fig 1. Changes in median scores for SF-36 Physical Domain
before and after treatment (N  50). Score 0-100 scale points, a
high score indicates a less perceived health problem. BP, bodily
pain; GH, general health; PF, Physical-Functioning; RP, role-
physical. Significant differences according to Wilcoxon signed
ranks test. (**P  .01, ***P  .001).
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Fig 2. Changes in median scores for SF-36 Mental Domain be-
fore and after treatment (N 50). Score 0-100 scalepoints, a high
score indicates a less perceived health problem.MH,mental health;
RE, role-emotional; SF, social-functioning; VT, Vitality. Signifi-
cant differences according to Wilcoxon signed ranks test (*P 
.05).cepted a treatment risk of death of 13%. This risk atti-tude, as well as the TTO question, displayed a consider-
able variation. Before surgery, for instance, 66% (N 
33) of the patients were willing to trade off 2 to 8 years
(TTO) of their remaining life and 34% (N  17) were
willing to accept a deadly risk of 48% to 96% (SG) with
the invasive treatment. The proportion of patients not
willing to trade years or accept any deadly risk was 34%
and 46%, respectively.
When our patients were asked re-evaluate their risk
attitude to treatment after revascularization they expressed
almost the same health utility values as they did before the
intervention. This suggests that the patients still are willing
to accept a substantial treatment risk even with the experi-
ence of the angioplasty or open bypass.
Cost-utility analysis
The EQ-5D index value increased from 0.51 to 0.68
after treatment, corresponding with a QALY gain of 0.17.
Accordingly, with an estimated survival of 5 years, revascu-
larization resulted in a gain of 0.85 (5 0.17) QALYs. The
total estimated cost for an endovascular intervention was, at
the time of the study, 5500 US$ and 11,000 US$ for an
open bypass. The ICER for endovascular treatment was
6500 US$ (5500/0.85) and for by pass surgery 13,000
US$ (11,000/0.85) which can be considered to be cost
effective according to the threshold for ICER recom-
mended by the NICE group.
Association between utility values, HRQL, and
clinical parameters
Health utility values and HRQL correlated to clinical
parameters. The correlation was weak between EQ-5D
index and ACD before (rs  0.43, P  .001), and after
(rs  0.34, P  .01) treatment. A similar but even weaker
correlation was found before treatment for ABPI (rs 
0.28, P  .004). The EQ-5D index also correlated signif-
icantly with most WIQ parameters. The individual utility
pre
post
time
WIQ A pain WIQ distance WIQ speed WIQ Stairs
Category
0
25
50
75
100
Va
lu
e
Α
Α
Α
Α
Α
Α Α
Α
Α
Α
ΑΣ
Σ
Σ
************
Fig 3. Changes in median scores for Walking Impairment Ques-
tionnaire (WIQ) before and after treatment (N  50). Score 100
indicates no problem with walking ability. Significant differences
according to Wilcoxon signed ranks test (***P  .001).measures, TTO and SG, displayed weak associations with
oxon
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lated to TTO preoperatively (rs  0.21, P  .03). Other
examples are the correlations between TTO and EQ mo-
bility (rs  0.20, P  .04) and WIQ pain (rs  0.22, P 
.02) before treatment. The SG correlated weakly with
ABPI before treatment (rs0.32, P .01) showing that
patients with a higher ABPI are willing to take less risk.
DISCUSSION
The main findings in this study were that: (1) patients’
perceived physical functional status was related to their risk
attitude; (2) patients are willing to accept a substantial risk
with the intervention; and (3) invasive treatment of severe
IC seems to be cost effective.
The result from the SF-36 is in agreement with another
study evaluating HRQL in patients with IC and critical
ischemia,28 but the scores were lower than in the general
Swedish population aged 65 to 69 years.17 The EQ-5D
self-classifier scores were also lower than in a general Swed-
ish population aged 60 to 69. Our IC patients perceived
more problems in all dimensions29 and the patients’ ability
to walk as assessed by the WIQ questionnaire was much
worse than in a study aiming to improve the walking ability
in IC patients by Cilostazol treatment.30 This difference is
Table II. Utility values for EQ-5D index, EQ visual analo
gamble (SG) before and after treatment (n  50)
Before
Mean (SD) Median
95% CI
Lower Upp
EQ-5D index 0.51 (0.28) 0.66 0.43 0.5
EQ-VAS 0.58 (0.18) 0.60 0.52 0.6
TTOa 0.71 (0.24) 0.70 0.64 0.7
SGa 0.74 (0.31) 0.88 0.65 0.8
Score 0-1.0, a high score indicates full health.
aRe-evaluation after treatment that assessed the preoperative situation (Wilc
Table III. Distribution (percentage) of respondents
reporting no problems, moderate, or severe problems in
different dimensions of EQ-5D, before and after
treatment (n  50)
No problem
n (%)
Moderate
n (%)
Severe n
(%)
Mobility pre 9 (18) 41 (82) 0
Mobility post 21 (43) 28 (57) 0
Self-care pre 48 (96) 2 (4) 0
Self-care post 50 (100) 0 0
Usual activity pre 24 (48) 22 (44) 4 (8)
Usual activity post 30 (61) 17 (35) 2 (4)
Pain pre 2 (4) 35 (70) 13 (26)
Pain post 7 (14) 38 (78) 4 (8)
Anxiety pre 26 (52) 22 (44) 2 (4)
Anxiety post 29 (60) 20 (40) 0likely due to the fact that the patients in our study hadmoresevere IC and were more homogeneous in respect of their
walking problems.
The improvement in HRQL after revascularization was
similar to what has been reported by other studies evaluat-
ing IC patients.31,32 Unanimously, it is the physical health
dimension that improves and the change correlates to
objective measures of a successful intervention such as ABI
improvement and longer walking distances. When compar-
ing the clinical results with two randomized trials evaluat-
ing surgical intervention, physical exercise, and no treat-
ment for IC patients, the ABPI improvement was similar
but the change in walking distance differed considerably.
Our patients had much shorter walking distance after 6
months.33,34 This may be explained by the number of
patients with bilateral disease that only got unilateral treat-
ment.
The patients’ improved HRQL after treatment was
reflected in their health utility values. There are few com-
parable studies using TTO, SG, and EQ-5D index in IC
patients. One study assessed HRQL after angioplasty and
stenting and compared with this cohort, our patients per-
ceived a better health state but were prepared to trade off
more years and accept a higher treatment risk.35 The dif-
ference regarding EQ-5D index is difficult to explain, con-
sidering that our patients had lower ABPI and shorter
walking distances before treatment than in that study.
Cultural differences may be one reason but it is also possible
that the age difference between the cohorts could have
been a contributing factor. Our patients were older and
may have been accustomed to a poor health state.36 The
age difference, together with physical problems such as pain
and short walking distance, may explain the high risk will-
ingness in our study compared with the mentioned study
by Bosch et al,35 but it might also have been influenced by
the fact that our patients already had accepted invasive
treatment when enrolled into the study. We noted higher
values comparing the individual TTO with the EQ-5D
index societal values both before and after treatment in our
cohort. These findings are usually interpreted in the litera-
ture as a result of a coping mechanism.42 It was also
observed in a Swedish general population sample, except in
the age group over 80 years. For older ages, theUKEQ-5D
scale (EQ-VAS), time trade-off (TTO), and standard
After
Mean (SD) Median
95% CI
P valueLower Upper
0.68 (0.22) 0.73 0.62 0.74 .0001
0.64 (0.22) 0.70 0.58 0.71 .02
0.74 (0.22) 0.70 0.68 0.81 .43
0.71 (0.29) 0.75 0.63 0.79 .52
signed ranks test).gue
er
9
3
8
2index appears to underestimate the health status severity
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instrument.37
In relation to other diseases that are considered not to
have a life-threatening implications, our EQ-5D health
utility value for IC of 0.51 is in the same range or slightly
higher as that reported; 0.41 for stable angina, 0.38 for hip
arthrosis, and 0.50 for esophagitis.38-40
Some patients had problems understanding and an-
swering the hypothetical TTO and the SG questions, and it
was generally apparent that it was much easier for patients
to relate to questions about treatment risk rather than
envision shortening of their lives. It is possible that the
information they already received by their surgeons facili-
tated the process of imagining treatment risk in relation
to their walking problems. This observation also suggests
that the SG utility scores are more reliable than the TTO
ones. The number of patients who chose not to trade off
years or take a deadly risk could be seen as more risk averse
according to the concept of risk attitude and utility theory.23
In addition, this group of patients perceived their HRQL
better which could explain their risk attitude. There is a
debate concerning the most appropriate method of mea-
suring patients’ preference. In a study trying to determine
the construct validity of TTO and SG, the SG showed the
best validity.41
To our knowledge, there are no studies addressing
cost-utility changes after surgical interventions in IC pa-
tients. One study assessed HRQL after infrainguinal bypass
grafting in patient with either IC or critical limb ischemia
(CLI), and in this cohort, the EQ-5D derived health state
was worse after revascularization than in our study.42 This
difference is probably explained by the inclusion of CLI
patients and more complications after surgery in that study.
The magnitude of improvement in EQ-5D derived QALY
values of 0.17 in our study was slightly lower than in the
previously mentioned report by Bosch evaluating angio-
plasty in patients with longer walking distances.35 The
cost-utility analysis in our study suggests that the utility
values derived from EQ-5D index are improved by revas-
cularization, and that it corresponds to an addition of 0.85
QALY over a 5-year period. Accordingly, invasive treat-
ments indicated by severe IC symptoms appear to be cost
effective. Our cost analysis did not consider external costs
and thus may underestimate expenditure. The difference in
true cost per QALY and per procedure was quite substan-
tial, however, and even after adding external costs it is
unlikely that it will reach the cost-effectiveness limit pro-
posed by the NICE group or in the literature. Accordingly,
we believe that this information can be communicated to
health authorities and primary care physicians with some
caution. Our analysis did not evaluate the societal cost
effectiveness of treatment,43 and it provides a rather short
follow up. Upcoming reports from our cohort will try to
address these issues. If the observed cost effectiveness still
remains a new similar study could focus on demonstrating
whether patients with less severe IC is cost effective to treat,
which could lead to extended indications earlier in the
course of the IC disease.It is the surgeon’s obligation to consider the patient’s
views and to include them in the decision-making process
when planning treatment, especially when a clinical deci-
sion contains risk and uncertainty.44 Accordingly, it is
probably important for the surgeon to consider the IC
patients’ rather high risk-willingness when discussing treat-
ment alternatives. Moreover, patients attitude to risk may
influence the choice of treatment more than the surgeon
may think is appropriate.
The limitations of this study are the potential problem
concerning interpretation of the health utility results and
overall risk perception since the patients were enrolled after
accepting surgical treatment. The reason for choosing this
design was that we wanted to study the effect of the
intervention and, therefore, needed patients we knew
would undergo surgery. We also compared patient risk
attitude before and after treatment andwe thought that this
comparison would be more appropriate if we enrolled
patients already cleared for surgery. The small sample size
and the limited follow-up for the cost-effectiveness analysis
are other limitations.
CONCLUSIONS
Patients with severe intermittent IC, who agreed to
undergo revascularization as well as assess their risk atti-
tude, are risk-seeking when it comes to surgical treatment,
and their risk attitude is correlated to their walking ability
and quality of life. The incremental QALYs gained by
treatment is achieved by a reasonable cost and appears to be
cost effective, at least in the short term.
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